

**TERMINAL DISCLAIMER TO ACCOMPANY PETITION**Docket Number
(Optional)

DM-6999A

In re Application of: Rajopadhye et al.

Name: DuPont Pharmaceuticals Company

Application Number: 09/599,890

Filed: June 21, 2000

For: VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS

The owner*, DuPont Pharmaceuticals Company of 100% percent interest in the above-identified application hereby disclaims a terminal part of the term of any patent granted the above-identified application equivalent to: (1) if the above-identified application is a design application, the period of abandonment of the above-identified application, and (2) if the above-identified application is a utility or plant application, the lesser of: (a) the period of abandonment of the application; or (b) the period extending beyond twenty years from the date on which the above-identified application was filed in the United States or, if the application contains a specific reference to an earlier filed application(s) under 35 U.S.C. 120, 121, or 365(c), from the date on which the earliest such application was filed. This disclaimer also applies to any patent granted on a utility or plant application filed before June 8, 1995, or a design application, that contains a specific reference under 35 U.S.C. 120, 121, or 365(c) to the above-identified application. This disclaimer is binding upon the grantee, and its successors or assigns.

Check either box 1 or 2 below, if appropriate.

1. ☐ For submissions on behalf of an organization (e.g. corporation, partnership, university, government agency, etc.), the person signing is empowered to act on behalf of the organization.
2. ☒ The undersigned is an attorney of record.

02/13/2002 JADD01 00000079 023850 09599890

03 FC:148 110.00 CH

Adjustment date: 04/02/2002 AKELLEY
02/13/2002 JADD01 - 00000079 023850 09599890
03 FC:148 110.00 CR

Signature

February 7, 2002

Date

Peter L. Dolan

Typed or printed name

- ☒ Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

* Certification under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.